10-K/A: UroGen Pharma Files Amendment No. 1 to 2024 Annual Report on Form 10-K/A

Sentiment:

Annual Report Amendment 30 April 2025 4:00 PM

UroGen Pharma files an amendment to its 2024 annual report to include information required by Part III of Form 10-K, covering directors, executive officers, compensation, security ownership, related transactions, and accountant fees.

Summary

UroGen Pharma Ltd. filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
The amendment provides information required by Part III of Form 10-K, including details on directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and principal accountant fees and services.
The filing includes updated certifications from the company's principal executive officer and principal financial officer.
The amendment does not reflect subsequent events occurring after the original filing date of the Form 10-K or modify or update the financial statements or other disclosures made in the original filing, except as required to reflect the amendments.
As of April 23, 2025, there were 46,107,451 of the registrant's ordinary shares outstanding.
The aggregate market value of the ordinary shares held by non-affiliates of the registrant as of June 28, 2024 totaled approximately $675.1 million.

Sentiment

Score: 6

Explanation: The document is a regulatory filing, so the sentiment is neutral. There are some positive aspects, such as revenue growth and strategic collaborations, but also negative aspects, such as not achieving revenue targets.

Positives

The company secured an exclusive license from medac GmbH to develop a next-generation novel mitomycin-based formulation for urothelial cancers.
A new U.S. patent was received that covers the use of UGN-103 and UGN-104 development programs, expiring in December 2041.
Strategic research collaborations were entered into to explore the potential of RTGel technology to enhance clinical effectiveness of multiple immunotherapies.
JELMYTO achieved net product revenue of $90.4 million in 2024, compared with $82.7 million in 2023, driven by underlying demand revenue growth of 12% for 2024.

Negatives

One of the corporate goals for 2024, achieving $100 million in revenue, was not achieved.
Stretch goals related to exceeding the $100 million revenue target and accelerating FDA acceptance of UGN-102 were not achieved.

Risks

The company's success is dependent on the FDA approval and commercialization of UGN-102.
Failure to achieve revenue targets could impact the company's financial performance and future growth.
The company faces risks associated with clinical development, regulatory approvals, and market competition.

Future Outlook

The company is awaiting the FDA's decision on its NDA for UGN-102, with a PDUFA target action date of June 13, 2025. The company is also focused on advancing its development programs and strategic collaborations to drive long-term growth.

Industry Context

UroGen Pharma is operating in the competitive biopharmaceutical industry, focused on developing and commercializing novel solutions for urothelial cancers. The company's success depends on its ability to navigate the regulatory landscape, secure partnerships, and effectively commercialize its products.

Comparison to Industry Standards

The document mentions a peer group of companies used for benchmarking executive compensation, including 2seventy bio, Arcus Biosciences, Day One Biopharmaceuticals, Deciphera Pharmaceuticals, Eagle Pharmaceuticals, Erasca, IDEAYA Biosciences, Inhibrx, iTeos Therapeutics, Karyopharm Therapeutics, Kura Oncology, RAPT Therapeutics, Rigel Pharmaceuticals, Syndax Pharmaceuticals, Tango Therapeutics, Verastem, Xencor and Y-mAbs Therapeutics.
The CEO's total direct compensation for 2024 was positioned at approximately the 20th percentile of the compensation peer group.
Non-CEO executives' total direct compensation for 2024 was positioned at approximately the 15th percentile of the compensation peer group.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Financial Officer	Don Kim	Chris Degnan	October 8, 2024	Don Kim resigned

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Compensation Policy	Shareholders approved an increase of the annual cash compensation for non-employee directors from $40,000 to $45,000 for their service on the Board, except for our Chair, Dr. Belldegrun, who received $195,000 for his service as Chair of our Board.	August 2024	Increased compensation for non-employee directors.

Related Party Transactions

Monograph Capital Partners I, L.P., affiliated with former director Dr. Cohen, purchased 1,572,327 Shares in a private placement for $15.0 million.
Entities affiliated with Arie Belldegrun, M.D., the Chair of the Board of Directors of the Company, held certain promissory notes of IconOVir that may entitle such entities to receive, in the aggregate, approximately 28.3% of the Purchase Price.

Stakeholder Impact

Shareholders: The company's performance and strategic decisions impact shareholder value.
Employees: Executive compensation and benefit plans affect employee morale and retention.
Patients: The development and commercialization of new therapies impact patient outcomes.
Creditors: The company's financial performance affects its ability to meet its debt obligations.

Next Steps

The company awaits the FDA's decision on the UGN-102 NDA.
The company will continue to advance its development programs and strategic collaborations.
The next say-on-pay vote will be held at the 2025 annual meeting of shareholders.

Key Dates

Date	Description
December 2012	Arie Belldegrun, M.D., FACS has served as our Chair of the Board since December 2012.
October 2017	Cynthia M. Butitta has served as our director since October 2017.
December 2017	Mark P. Schoenberg, M.D. has served as our Chief Medical Officer since December 2017.
January 3, 2019	Elizabeth Barrett has served as our President and Chief Executive Officer and as a director since January 2019.
August 12, 2020	Jason Smith has served as our General Counsel, Chief Compliance Officer and Corporate Secretary since August 2020.
August 2022	Leana S. Wen, M.D., M.Sc. has served as our director since August 2022.
November 2022	Daniel G. Wildman has served as our director since November 2022.
July 2023	James A. Robinson, Jr. has served as our director since July 2023.
October 8, 2024	Chris Degnan has served as our Chief Financial Officer since October 2024.
October 8, 2024	Don Kim resigned from his positions as the Company's Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective October 8, 2024.
October 2024	The NDA for UGN-102 was accepted in October 2024 and is under review by the FDA.
December 31, 2024	Fiscal year ended December 31, 2024.
January 2025	The Board reviewed and approved corporate cash incentives in January 2025.
February 14, 2025	The Company entered into an Asset Purchase Agreement with IconOVir Bio, Inc. on February 14, 2025.
April 23, 2025	As of April 23, 2025, there were 46,107,451 of the registrant's ordinary shares outstanding.
April 30, 2025	Filing date of Amendment No. 1 to the annual report on Form 10-K/A.
June 13, 2025	PDUFA target action date set for June 13, 2025, for the NDA for UGN-102.

Keywords

executive compensation, directors, corporate governance, UGN-102, JELMYTO, financial results, UroGen Pharma, amendment, 10-K

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.